| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/14/2004 | EP1436279A1 Chemical compounds |
| 07/14/2004 | EP1436273A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof |
| 07/14/2004 | EP1436272A1 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors |
| 07/14/2004 | EP1436271A1 Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
| 07/14/2004 | EP1436270A1 Novel benzothiazine derivatives, their preparation and use |
| 07/14/2004 | EP1436269A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1436268A1 Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them |
| 07/14/2004 | EP1436267A1 Lactam derivatives as antagonists for human 11cby receptors |
| 07/14/2004 | EP1436266A2 Methods and compositions of novel triazine compounds |
| 07/14/2004 | EP1436264A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
| 07/14/2004 | EP1436259A1 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors |
| 07/14/2004 | EP1436258A2 Ph-dependent nmda receptor antagonists |
| 07/14/2004 | EP1436257A1 Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3 |
| 07/14/2004 | EP1436255A1 Novel compounds and compositions as cathepsin inhibitors |
| 07/14/2004 | EP1436253A1 Acylsulfonamides as inhibitors of steroid sulfatase |
| 07/14/2004 | EP1436252A1 Hydroxyfattysulfonic acid analogs |
| 07/14/2004 | EP1436250A1 Cyanoacetyl compounds |
| 07/14/2004 | EP1436249A2 Muscarinic agonists |
| 07/14/2004 | EP1436247A1 Novel-beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds |
| 07/14/2004 | EP1436246A1 Oligoamine compounds and derivatives thereof for cancer therapy |
| 07/14/2004 | EP1436013A2 Method for inducing growth and enhancing survival of nervous tissue |
| 07/14/2004 | EP1436012A2 Polymer conjugates of opioid antagonists |
| 07/14/2004 | EP1436011A2 Dendrimers for use in targeted delivery |
| 07/14/2004 | EP1436010A2 Water-in-oil emulsions comprising vinyl polymers carrying ethylene oxide groups in side chains, compositions, and methods |
| 07/14/2004 | EP1436009A1 Pharmaceutical formulation |
| 07/14/2004 | EP1436008A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| 07/14/2004 | EP1436007A2 Compounds for use as surfactants |
| 07/14/2004 | EP1436006A2 Viral inhibition by n-docosanol |
| 07/14/2004 | EP1436005A1 Inhibition of neonatal hyperbilirubinemia in breast fed infants |
| 07/14/2004 | EP1436000A2 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
| 07/14/2004 | EP1435998A1 Method for treating hepatitis c virus infection in treatment failure patients |
| 07/14/2004 | EP1435997A1 Method for treating hepatitis c virus infection in treatment failure patients |
| 07/14/2004 | EP1435995A2 Composition and method for treating diabetes |
| 07/14/2004 | EP1435994A2 Novel use of pulmonary surfactant |
| 07/14/2004 | EP1435993A2 Utilisation d'une proteine de la famille des crmps pour le traitement des maladies liees au systeme immunitaire |
| 07/14/2004 | EP1435988A1 Improved use of antitumoral compound in cancer therapy |
| 07/14/2004 | EP1435987A1 Method and composition for treating immune complex associated disorders |
| 07/14/2004 | EP1435986A2 Igf-binding protein-derived peptide or small molecule |
| 07/14/2004 | EP1435984A1 Use of histamine to treat liver disease |
| 07/14/2004 | EP1435983A1 Concentrate comprising green tea, grape skin extract and grape seed extract, the production thereof and the use of the same |
| 07/14/2004 | EP1435976A1 Pharmaceutical composition comprising chito-oligomers |
| 07/14/2004 | EP1435974A2 Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| 07/14/2004 | EP1435973A1 Coadministration of transport protein with conjugated cobalamin to deliver agents |
| 07/14/2004 | EP1435972A2 Novel synthetic ganglioside derivatives and compositions thereof |
| 07/14/2004 | EP1435971A1 Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs) |
| 07/14/2004 | EP1435970A2 Methods of treating skin with diphosphonate derivatives |
| 07/14/2004 | EP1435969A2 Method of modulating sodium ion absorption in epithelial cells |
| 07/14/2004 | EP1435968A1 Combinations comprising cox-2 inhibitors and aspirin |
| 07/14/2004 | EP1435967A2 Methods for preventing and treating bone loss with steroid compounds |
| 07/14/2004 | EP1435966A2 Method for inhibiting the proliferation of hepatic stellate cells with a ligand of the low affinity glucocorticoid binding site (lags) |
| 07/14/2004 | EP1435965A2 Pharmaceutical compositions and methods for treating cancer |
| 07/14/2004 | EP1435963A2 Reduced toxicity cisplatin formulations and methods for using the same |
| 07/14/2004 | EP1435962A2 Treatment of type i diabetes |
| 07/14/2004 | EP1435961A2 Treatment for lupus erythematosus |
| 07/14/2004 | EP1435960A1 Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists |
| 07/14/2004 | EP1435959A2 Inhibitors of the egf receptor for the treatment of thyroid cancer |
| 07/14/2004 | EP1435958A1 Use of phosphorodiesterase iv inhibitors |
| 07/14/2004 | EP1435957A2 Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes |
| 07/14/2004 | EP1435956A2 Therapeutic combinations for cardiovascular and inflammatory indications |
| 07/14/2004 | EP1435955A2 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 07/14/2004 | EP1435954A1 High purity amlodipine benzenesulfonate and a process for its preparation |
| 07/14/2004 | EP1435952A1 8-amino- 1,2,4]triazolo 1,5-a]pyridine-6-carboxylic acid amide |
| 07/14/2004 | EP1435951A1 Phenyl substituted 5-membered nitrogen containing heterocycles for the tretment of obesity |
| 07/14/2004 | EP1435950A1 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1435949A1 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1435948A1 Aminoisoxazole derivatives active as kinase inhibitors |
| 07/14/2004 | EP1435947A1 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cds1/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer |
| 07/14/2004 | EP1435946A2 Linked biaryl compounds |
| 07/14/2004 | EP1435945A1 Transdermal migraine therapy |
| 07/14/2004 | EP1435944A1 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| 07/14/2004 | EP1435943A2 Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug for treating dyskinesia |
| 07/14/2004 | EP1435942A1 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1435941A2 Wortmannin analogs and methods of using same |
| 07/14/2004 | EP1435940A1 Treatment of scleroderma |
| 07/14/2004 | EP1435938A1 Modulation of ocular growth and myopia by gaba drugs |
| 07/14/2004 | EP1435937A2 Composition comprising paracetamol and a bitterness masking component |
| 07/14/2004 | EP1435936A1 5'-carbamoyl-1,1-biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1435935A2 Concentrated x-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions |
| 07/14/2004 | EP1435934A1 5'-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1435933A1 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 07/14/2004 | EP1435932A2 Inhibitors of rnase p proteins as antibacterial compounds |
| 07/14/2004 | EP1435931A2 Dosage form for treatment of diabetes mellitus |
| 07/14/2004 | EP1435930A2 Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications |
| 07/14/2004 | EP1435929A1 Composition comprising cysteamine for improving lactation in dairy animals |
| 07/14/2004 | EP1435928A1 Allicin |
| 07/14/2004 | EP1435927A2 Method for treating skin disorders |
| 07/14/2004 | EP1435926A2 Method for treatment and prevention of disturbances of the central nervous system associated with an alteration of glutamatergic neurotransmission by administration of 2-aminobenzenesulfonamide derivatives |
| 07/14/2004 | EP1435925A2 Gap junctions and edhf |
| 07/14/2004 | EP1435924A2 Therapeutic composition and use |
| 07/14/2004 | EP1435923A2 Methods and apparatus for improved administration of analgesics |
| 07/14/2004 | EP1435921A1 Use of a multi-layer controlled-release tablet comprising ropinirole for the manufacture of medicament for the treatment of fibromyalgia |
| 07/14/2004 | EP1435918A1 Highly compressible ethylcellulose for tableting |
| 07/14/2004 | EP1435917A1 Solid pharmaceutical formulation for a piperazine urea derivative |
| 07/14/2004 | EP1435916A1 Powder processing with pressurized gaseous fluids |
| 07/14/2004 | EP1435915A1 Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient |
| 07/14/2004 | EP1435913A2 Method of treating benign prostatic hyperplasia and other beingn porstate conditions |
| 07/14/2004 | EP1435909A1 Stable composition comprising particles in a frozen aqueous matrix |
| 07/14/2004 | EP1435908A1 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
| 07/14/2004 | EP1435907A2 Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity |
| 07/14/2004 | EP1435905A1 Binary composition for "prime-boost" release of active ingredients like vaccines |